// App-Quantinova.ai

SAT0166 : BIOMARKERS OF B-CELL DEPLETION AND RESPONSE IN A RANDOMIZED, CONTROLLED TRIAL OF OBINUTUZUMAB FOR PROLIFERATIVE LUPUS NEPHRITIS

Researchers

Presenter

  • E. Vital

Principal Investigators

  • P. Rmy

  • L. F. Quintana Porras

  • L. Chiche

  • D. Chauveau

  • R. Furie

  • T. Schindler

  • J. Garg

  • M. D. Cascino

  • Z. Amoura

  • A. Doria

  • C. M. D. Looney

  • D. Roccatello

Medical Centers

  • University of Leeds, Leeds, United Kingdom

  • Groupe Hospitalier Henri Mondor, Creteil, France

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Hopital Europeen, Marseille, France

  • Hôpital Rangueil, Centre Hospitalier Univ de Toulouse, Toulouse, France

  • Northwell Health, Great Neck, United States

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Genentech Inc., San Francisco, United States

  • Hôpital La Salpêtrière, Paris, France

  • Univ of Padova, Padova, Italy

  • S Giovanni Hospital, Univ of Turin, Turin, Italy

Locations

  • United Kingdom

  • France

  • Spain

  • United States

  • Switzerland

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Autoimmune (AI)

Disease

  • Lupus nephritis

Biomarkers

  • B-cell activating factor

Drug/Treatment

  • Glucocorticoid

  • Mycophenolic acid

  • Obinutuzumab

  • Obinutuzumab Intravenous

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • NCT02550652

  • NCT04221477

Sponsors

  • Roche Holding AG

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved